19 August 2009
Sue Sutter
The US FDA has cited Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) for "objectionable conditions" in two clinical trials for the investigational antibiotic ceftobiprole.
The warning letter says J&JPRD failed to ensure proper monitoring of the studies and to...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Basilea’s antibiotic trials (and tribulations) may resolve in Q4
- US Capitol Capsule: PhRMA hopes Part D savings will be muscle against 'Super Congress' cuts
- US Capitol Capsule: Zombies, doomsday and debt ceilings, oh my
- Indian CROs may feel the heat after local firm, Axis, is suspended
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
